Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
992.34
+5.07 (+0.51%)
Streaming Delayed Price
Updated: 12:12 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
2 Top Growth Stocks to Buy With $1,000 Right Now
February 18, 2024
Even a modest starting investment in the right stocks could pay off in the years ahead.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
February 12, 2024
Via
Benzinga
These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?
February 09, 2024
There's room for multiple winners in the fast-growing weight-loss market.
Via
The Motley Fool
The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition
February 06, 2024
Some of the best stocks to buy in February according to MarketMaster AI suggest that a major economic recovery is underway.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast
February 06, 2024
4D Molecular Therapeutics' 4D-150 Phase 2 results for wet AMD treatment. BMO Capital optimistic, target price raised to $70.
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $6,400 Today
February 06, 2024
Via
Benzinga
Earnings Outlook For Regeneron Pharmaceuticals
February 01, 2024
Via
Benzinga
Breaking Down Regeneron Pharmaceuticals: 14 Analysts Share Their Views
January 29, 2024
Via
Benzinga
Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
February 06, 2024
Via
Benzinga
Stock-Split Watch: Could These 2 Market-Beaters Be Next?
February 06, 2024
Investors might continue bidding up shares of these companies regardless.
Via
The Motley Fool
Why Is Eye Disease-Focused 4D Molecular Therapeutics Stock Shooting Higher Today?
February 05, 2024
4D Molecular Therapeutics data in wet AMD treatment. Phase 2 PRISM trial shows promising results - 89% reduction in anti-VEGF injections, stable visual acuity.
Via
Benzinga
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
February 02, 2024
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
February 02, 2024
The Dow led the major indexes higher. Big techs diverged on results.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today?
February 02, 2024
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77.
Via
Benzinga
The Surprising Sources Of Regeneron's Fourth-Quarter Beat As Shares Hit Another Record High
February 02, 2024
Shares usually rally on Eylea news, but Regeneron stock is on the rise following fourth-quarter beats from two other products.
Via
Investor's Business Daily
Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year
February 02, 2024
Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc.
Via
Benzinga
Earnings Scheduled For February 2, 2024
February 02, 2024
Companies Reporting Before The Bell • W.W. Grainger (NYSE:GWW) is likely to report quarterly earnings at $8.05 per share on revenue of $4.04 billion.
Via
Benzinga
3 Top Pharma Stocks to Buy Now: February 2024
February 01, 2024
Discover why these three pharma stocks should be on your buy list in February 2024 - they could be your ticket to explosive portfolio growth.
Via
InvestorPlace
Sanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't.
February 01, 2024
The company missed total sales and earnings expectations.
Via
Investor's Business Daily
AI, Biotech, Energy Sectors Expect M&A Revival For 2024
January 29, 2024
The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
3 Magnificent Stocks to Buy and Hold Forever
January 27, 2024
Many investors will want to consider owning these stocks for a long time.
Via
The Motley Fool
Regeneron/Sanofi's Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation
January 26, 2024
FDA approves Dupixent (dupilumab) by Regeneron/Sanofi for pediatric eosinophilic esophagitis treatment. Breakthrough treatment for young patients.
Via
Benzinga
Exposures
Product Safety
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
January 29, 2024
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts
January 24, 2024
UBS insights on Biogen Inc's challenges with Leqembi in the Alzheimer's market. Analyst downgrades, revised sales estimates, and CEO's growth strategy.
Via
Benzinga
3 Blue-Chip Healthcare Stocks to Buy and Hold Forever: January 2024
January 23, 2024
Blue-chip healthcare stocks combine stability, profitability, and long-term growth prospects into a single investable package.
Via
InvestorPlace
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024
January 22, 2024
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD.
Via
Talk Markets
Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
January 22, 2024
HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape.
Via
Benzinga
2 Smart Growth Stocks to Buy Hand Over Fist in 2024
January 21, 2024
These businesses are on paths to extremely bright futures.
Via
The Motley Fool
EXCLUSIVE: The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker
January 18, 2024
The "buy everything" sentiment that powered equity indices higher last quarter is over. It's a stock picker's market, Marc Chaikin says.
Via
Benzinga
Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83
January 18, 2024
On Thursday, Ultragenyx Pharm stock just cleared that 80 or higher RS Rating benchmark with an upgrade from 75 to 83.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.